secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045628
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Therapeutics prices $52.5M public offering of units with warrants
------------------------------------------------------------------------

- Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
- Each unit: one share common + Series A warrant (1 share at $0.80, 5yr) + Series B warrant (0.5 share at $0.70, expires June 30, 2026).
- Offering expected to close March 5, 2025; Leerink Partners and Piper Sandler are joint book-runners.
- Net proceeds to fund development of TN-201 and TN-401, and for working capital.
- Company also terminated ATM prospectus under existing sales agreement with Leerink Partners as of March 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525045628/0001193125-25-045628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312525045628/d878268d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer